EUCTR2021-000682-32-ES进行中（未招募）1 期
A First in human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients enrolling into Part 1 (Phase 1), or Part 2 (Phase 2a) must meet all of the following inclusion criteria:
- •1. Adults = 18 years of age (or the legal age of majority in the country of recruitment) at the time consent is obtained
- •2. Patient should understand, voluntarily sign, and date the written consent form prior to any protocol-specific procedures
- •3. Performance Status score less than or equal to 1 according to the Eastern Cooperative Oncology Group (ECOG) scale.
- •4. Have histological or cytological evidence of a diagnosis of pancreatic cancer that is advanced and/or metastatic
- •5. Have a life expectancy of = 3 months
- •6. No other malignancy present that would interfere with the current intervention
- •7. Prior radiation therapy for treatment of cancer is allowed to < 25% of the bone marrow, and patients must have recovered from the acute toxic effects of their treatment prior to study enrolment. Prior radiotherapy must be completed at least 4 weeks before the first dose of study treatment
- •8. At least one measurable lesion as per RECIST v1.1
- •9. Adequate baseline organ function defined as:
- •a. Absolute Neutrophil Count = 1.5 × 10^9 /L
- •b. Haemoglobin = 9 g/dL
- •c. Platelets = 100 × 10^9/L
- •d. Total bilirubin = 2 × ULN (= 3 x ULN for patients with biliary stenting)
- •e. AST and ALT < 3 x ULN (= 5 x ULN for patients with hepatic metastases)
- •f. Serum creatinine OR creatinine clearance (as determined by the Cockcroft Gault formula) OR eGFR based on MDRD = 1.5 x ULN OR = 50 mL/min OR = 50 mL/min/1.73 m^2
- •g. LVEF = 50% by ECHO or MUGA
- •h. QTc = 470 ms
- •10. Female patients of nonchildbearing potential, must meet at least 1 of the following criteria: have undergone a documented hysterectomy, and/or bilateral oophorectomy; have medically confirmed ovarian failure or achieved postmenopausal status. A postmenopausal state is defined as cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have a follicle-stimulating hormone (FSH) level confirming the postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. Female patients of childbearing potential must have a negative serum pregnancy test within 28 days prior to and negative urine pregnancy test just prior to the first dose of PBP1510 and agree to use effective contraception, in accordance with the recommendations of the Clinical Trials Facilitation and Coordination Group (CTFG) from study entry and until for at least 6 months after the last dose of PBP1510
- •11. For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception (e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive hormone implants) from study entry and until for at least 6 months after the last dose of PBP1510. Investigator or his/her representative should discuss acceptable pregnancy prevention method(s) with the patients. Highly effective methods of birth control include those that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, levonorgestrel-releasing intrauterine system, intrauterine devices (IUD), and true sexual abstinence
- •12. Patients must be willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, contraceptive guide
排除标准
- •Patients enrolling into Part 1 (Phase 1), or Part 2 (Phase 2a) will be excluded if any of the following criteria apply:
- •1. Patients who have known brain metastases will be excluded from the study. However, a patient may be included in the study, if has been previously treated for brain metastasis, the disease is well controlled for at least 3 months, and the patient is off steroids.
- •2. Patients who have undergone a major surgery within 4 weeks prior to the start of PBP1510 administration, other than endoscopic/radiation procedures, bypass surgery (e.g., gastrojejunostomy), laparoscopy, port placement or a diagnostic surgery (i.e., surgery done to obtain a diagnostic biopsy, without removal of an organ), as long as the patient has recovered from these minor surgical procedures.
- •3. Patients who have active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, e.g., an active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, Pneumocystis carinii (P. carinii), or other microorganisms that is under treatment with myelotoxic drugs.
- •4. Patient has a known history of human immunodeficiency virus (HIV; HIV 1/2 antibodies).
- •5. Patient has known history of or currently active hepatitis B (e.g., hepatitis B antigen [HBsAg] reactive), hepatitis C (e.g., HCV RNA [qualitative] is detected) or syphilis [Venereal Disease Research Laboratory (VDRL) to detect antibodies in blood]).
- •6. Patient has impaired cardiac function and uncontrolled cardiac diseases/hypertension that are deemed clinically significant by the Investigator and which could compromise the patient’s safety or the study data integrity.
- •7. Patient has serious psychiatric disorders, which could compromise the patient’s safety or the study data integrity.
- •8. Any other malignancy from which the patient has been disease-free for less than 5 years, except for adequately treated and cured basal or squamous cell skin cancer.
- •9. Patients who are enrolled in any other therapeutic clinical trial.
- •10. Patients currently receiving radiation therapy or those having received radiation within 4 weeks prior to study entry.
- •11. Patients having received investigational anti-cancer drug within 28 days (or 5 half-lives, whichever is longer) preceding the first dose of PBP1510 or chemotherapy within the last 4 weeks prior to the first dose of PBP1510.
- •12. Patients with known allergy or hypersensitivity to components of the PBP1510 formulation including the excipients and history of hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies.
- •13. Patients who are pregnant, or breast feeding.
- •14. Patients who are unwilling or unable to comply with study procedures.
- •15. Patients who are not eligible to participate in this study, as judged by Investigators.
- •16. A history of allergic reactions attributed to gemcitabine or compounds of similar chemical composition to gemcitabine.
- •Note: Patients with previous exposure to gemcitabine should not be excluded from the study.
研究者
相似试验
招募中
1 期
A study to assess safety, tolerability, and anticancer activity of ISB 1442CTRI/2024/04/065308Ichnos Sciences SA
终止
1 期
A Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In patients With Solid Tumorseoplastic Disorder - Solid TumorsNeoplastic Disorder - Solid TumorsCancer - Any cancerACTRN12621001342808ChemoCentryx, Inc21
尚未招募
1 期
A First-in-Human Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple MyelomaRelapsed Multiple MyelomaRefractory Multiple MyelomaCancer - MyelomaACTRN12622000856718Ichnos Sciences SA121
招募中
1 期
A First-in-Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients With Advanced TumorsSolid Tumorsrelapsed/refractory Non-Hodgkin’s lymphomas (NHL)Cancer - Any cancerACTRN12622001339741Tigermed Australia Pty Ltd36
招募中
1 期
Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancerSolid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065143Term: Malignant solid tumour Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10043302Term: Testicular cancer Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10007460Term: Carcinoma of unknown primary Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2024-512639-58-00BioNTech SE330